Hiroaki Taniai
About
In The Last Decade
Hiroaki Taniai
18 papers receiving 389 citations
Peers
Comparison fields: 5 of 77
- Epidemiology 156
- Hepatology 118
- Molecular Biology 96
- Infectious Diseases 78
- Endocrinology 62
Countries citing papers authored by Hiroaki Taniai
This map shows the geographic impact of Hiroaki Taniai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Taniai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Taniai more than expected).
Fields of papers citing papers by Hiroaki Taniai
This network shows the impact of papers produced by Hiroaki Taniai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Taniai. The network helps show where Hiroaki Taniai may publish in the future.
Co-authorship network of co-authors of Hiroaki Taniai
This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Taniai. A scholar is included among the top collaborators of Hiroaki Taniai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Taniai. Hiroaki Taniai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 36 | |
| 3 | 43 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 4 | |
| 8 | 46 | |
| 9 | 10 | |
| 10 | 1 | |
| 11 | 24 | |
| 12 | 6 | |
| 13 | 47 | |
| 14 | 83 | |
| 15 | 8 | |
| 16 | 74 | |
| 17 | 9 | |
| 18 | A Japanese case of severe refractory adult Still's disease: serum interleukin-18 is a possible marker of the response to low-dose cyclosporin A therapy. | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.